Launch a novel prenatal test combining Prequel and Foresight clinical value
Delivered after the deadline (1298 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Nov 2021
- Due
- 31 Dec 2022
- Delivered
- 21 Jul 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“In late 2022, the company plans to launch a novel prenatal test that will deliver the clinical value of both Prequel and Foresight to more expectant parents.”
What we found
Evidence strength A What the grades mean
Myriad launched FirstGene combining prenatal tests in July 2026, over 3 years after the late-2022 deadline stated in the November 2021 commitment.
-
A Myriad Genetics Q3 2021 Earnings Release
“In late 2022, the company plans to launch a novel prenatal test that will deliver the clinical value of both Prequel and Foresight to more expectant parents.” ✓ confirmed on the page
-
B Myriad Genetics Applauds New Guidelines
“Myriad Genetics also confirmed the upcoming product launch of FirstGene, an innovation that will enhance the ease-of-use and utility of prenatal screening” ✓ confirmed on the page
-
B Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
“today announces the full commercial launch of FirstGene® Multiple Prenatal Screen, the only lab test that runs four prenatal genetic screens simultaneously from a single blood draw” ✓ confirmed on the page
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Novel prenatal test
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Myriad Genetics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-MYGN-003906 · Corrections policy